BiOptix announces expansion of Board of Directors
BOULDER, Colo., June 27, 2012 /PRNewswire/ -- BiOptix announces the appointment of Michael W. Routh, Ph. D. to the Board of Directors of the firm, adding to a preeminent group of leaders driving BiOptix and its proprietary Enhanced Surface Plasmon Resonance platform toward continued success in the life science marketplace.
BiOptix, a leader in the Surface Plasmon Resonance space today announced the appointment of Michael W. Routh, Ph.D. to the Board of Directors. "The appointment of Dr. Routh brings a wealth of analytical instrument sector knowledge to BiOptix," noted Rick Whitcomb, President and CEO of BiOptix. "I'm excited to join the Board of Directors of BiOptix—BiOptix has a winning technology value proposition and will continue to exceed customer requirements with its proprietary Enhanced Surface Plasmon Resonance platform. BiOptix has a world-class team driving the scientific discovery and commercialization process and I'm glad to be a part of this success story," noted Dr. Routh.
Dr. Routh's career spans over 30 years in the analytical instrument industry split equally between top executive and senior functional leadership roles in such notable companies as Varian, Applied Research Laboratories, Baird, Thermo Fisher Scientific, BioRad and most recently, General Electric. Dr. Routh earned both B.S. and M.S. degrees at Fresno State University and a Ph.D. degree from the University of Arizona, all in Analytical Chemistry.
Dr. Routh joins the following individuals on the Board of Directors of BiOptix:
- William Freytag, Ph.D – Chairman of the Board
- Kyle Lefkoff – Director
- Ron Lowy – Director
- William Marshall, Ph.D – Director
- Konstantin V. Severinov, Ph.D – Director
- Sergey Polikarpov – Director
- Richard Whitcomb – Director, President & CEO, BiOptix
In addition, Dr. Routh will be working with the Management Team of BiOptix:
- Marty Stanton, Ph.D., Chief Scientific Officer
- Ken Wilczek, Vice President, Sales & Marketing
- Nolan Smith, Vice President, Finance
- Slava Petropavlovskikh, Director, Research & Development, Co-Founder BiOptix
BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
SOURCE BiOptix Diagnostics Corporation